Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Integral-2: Cefepime/nacubactam or aztreonam/nacubactam vs best available therapy for CRE infections
jRCT2031230076Phase 3Completed
- Sponsor
- Meiji Seika Pharma Co., Ltd.
- Start
- May 2023
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, single-blind trial of cefepime, aztreonam and Nacubactam in complicated urinary tract infection (cUTI), acute pyelonephritis, hospital-acquired pneumonia (HAP) and 3 more (3 arms), sponsored by Meiji Seika Pharma Co., Ltd. Started May 2023; status: completed.
02
Drugs
cefepimeaztreonamNacubactam
03
Conditions
complicated urinary tract infection (cUTI)acute pyelonephritishospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)Intra-abdominal infection (IAI)
Beyond the preview
Go deeper on jRCT2031230076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230076.